Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib + Spartalizumab vs Capmatinib in METex14 NSCLC
NCT04323436Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 9
01
Overview
A Phase 2 trial of spartalizumab in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Aug 2020; status: terminated.
02
Drugs
spartalizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04323436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04323436.